Drug Profile
NPO 13
Alternative Names: NPO-13Latest Information Update: 25 Aug 2020
Price :
$50
*
At a glance
- Originator Nihon Pharmaceutical
- Class Diagnostic agents
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Spasm
Most Recent Events
- 26 Mar 2020 Nihon Pharmaceutical completes a phase II trial in Spasm (Diagnosis) in Japan (Intraluminal) (NCT04097574)
- 26 Aug 2019 Nihon Pharmaceutical initiates enrolment in a phase II clinical trials in Spasm (Diagnosis) in Japan (Intraluminal) (NCT04097574)
- 22 May 2015 Nihon Pharmaceutical completed phase-II clinical trials in Gastrointestinal disorders (Diagnosis) in Japan (Intraluminal) (NCT02265939)